China-based Tasly Pharma Co., Ltd (SHA: 600535) has announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its generic version of Swiss pharmaceutical giant Novartis’ (NYSE: NVS) Lioresal (baclofen) in the form of an oral solution. This Category 3 chemical drug is now approved for use in treating severe but reversible muscle spasms caused by multiple sclerosis and has shown therapeutic effects on spasms resulting from various other conditions, including infectious, degenerative, or traumatic diseases, as well as tumors or unexplained spinal cord diseases.
Therapeutic Impact and Pediatric Drug Listing
Baclofen, initially approved in Ireland in 1984, was recognized for its importance in pediatric care and was included in the list of second batch pediatric drugs encouraged for development by the National Health Commission in 2017. This inclusion underscores the drug’s significance in addressing the needs of pediatric patients and its potential role in improving their quality of life.-Fineline Info & Tech
